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Background: Involving patients in treatment is becoming increasingly popular in mental health [Sales & Alves:
Personalized evaluation of psychological treatments: A review of tools and research designs, submitted]. However,
in substance misuse treatment settings, the patient perspective about treatment tends to be overlooked. This has
been cited as a key priority by Orford et al. [Addiction, 103: 875-885, 2008] who included patient feedback about
treatment as one of ten areas requiring an urgent paradigm shift in addiction research and practice.
This project will apply an innovative method to involve substance misuse patients in psychological therapies, by
asking them to suggest topics to evaluate their treatment. These topics suggested by patients can be written as a
list of personalised items, so-called as patient-generated outcome measures (PGOM). Despite its patient-friendly
features, PGOM’s have never been used in this population, which is what this project aims to overcome.
Methods/design: This project is part of an International Exchange Platform on Personalising Addiction Treatment.
Data will be collected in two phases (pre-post study and focus groups with patients) to explore the following:
1). How reliable and sensitive to change are PGOM’s and standardised measures in substance misuse treatment?
2). Do PGOM’s add relevant information to standardised measures?
3). What are the views of substance misuse patients about personalised outcome assessment?
4). Development of guidelines on using PGOM’s in this population
Discussion: This research will potentially demonstrate the diversity of personal problems among patients seeking
substance misuse treatment, suggesting the relevance of PGOM as a method to personalise outcome measurement
and, ultimately, guiding treatment provision. It is expected that, as in previous studies, PGOM’s will be perceived as
helpful and patient-friendly tools, where patients may express their own concerns in a semi-structured setting. Similarly
to other populations, we also expect PGOM’s to be reliable, valid and sensitive to clinical changes in substance misuse
treatment, as well as more content informative than their standardised counterparts. If these results are achieved, we
might hypothesize that PGOM’s are a potentially valid supplement to traditional standardised scales, by providing a
closer insight to what motivates patients to participate in substance misuse treatment programmes.
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Involvement of the patient in mental health care is cur-
rently a subject of intense debate [Sales & Alves: Person-
alized evaluation of psychological treatments: A review
of tools and research designs, submitted]. This approach
involves listening to the patient perspective, taking into
account his particular needs and his views about health
care processes [1,2]. Patient involvement with treatment
is already being implemented in various mental health
settings, such as psychiatric units [3] or primary mental
health care [4] with encouraging results. In substance
misuse treatment settings, the involvement of patients
is also deemed to be of great importance, both by re-
searchers [5] and policy makers (e.g. Institute on Drugs
and Drug Addiction, Portugal). However, in this context,
the patient perspective still remains often overlooked
and our project will contribute to reducing this gap.
Patients can be directly involved in healthcare at different
levels, such as service management, community initiatives,
public policy and treatment provision/planning. When it
comes to being involved with treatment, there are various
strategies that can be applied. On the one hand, the patient
perspective may be accessed with traditional standardised
tools that encompass pre-set and psychometrically determined
items. This is the most commonly used approach. Alterna-
tively, we might ask patients to propose the content of the
items, thus building a personalised questionnaire, containing
his or her personal problems or goals for therapy. Ashworth
and collaborators defined these as “patient-generated outcome
measures” (PGOM), put other way, “questionnaires where the
items to be measured are defined by the patient” [6].
Due to their open-ended structure, PGOM’s encourage
patients to express their point of view, hence allowing a
“personalised evaluation” of patient’s condition. For such
reason, we designate as “personalised outcome assess-
ment” all types of outcome assessment that use PGOM’s,
either alone or as an increment to traditional standar-
dised measures [3].
The use of personalised outcome assessment has been
growing in popularity in the last decades [Sales & Alves:
Personalized evaluation of psychological treatments: A
review of tools and research designs, submitted]. For
instance, previous studies have shown that psychothera-
pists find the routine use of PGOM’s useful for treatment
planning and decision-making [3,7]. Psychometrically,
PGOM’s appear to be more sensitive to detect clinical
change when compared with standardised scales [8].
Also in primary care, a recent study found that
PGOM’s were useful to identify different sub-types of
patients with a physical condition, based on their
patient-generated, self-reported problems [9]. From a
policy point of view, international health authorities,
such as the American Psychological Association (http://
www.divisionofpsychotherapy.org/continuing-education/task-force-on-evidence-based-therapy-relationships/con-
clusions-of-the-task-force/) or the United Kingdom’s
National Institute for Health and Care Excellence
(http://publications.nice.org.uk/quality-standard-for-
service-user-experience-in-adult-mental-health-qs14/
quality-statement-5-using-views-of-service-users-to-
monitor-and-improve-services) also advocate for the
active involvement of patients in their own treatment
(the ‘expert patient’) as a best-practice principle.
Despite this overall interest in patient involvement, the
patient perspective in substance misuse treatment settings
remains relatively unexplored and unheard (Orford, [5]).
According to Orford [1], this is one of the ten aspects
needing an urgent shift in the provision of substance treat-
ment, where patients tend to be misinformed about the
rationale behind their treatment plans [10]. Hence, listen-
ing to patients is a powerful strategy to explore what pa-
tients specifically need from treatment services, potentially
avoiding outcomes or early treatment drop-out. As a con-
sequence, it is extremely vital to study methodologies to
overcome this limitation.
To our knowledge, PGOM’s have never been used in
substance misuse treatment settings and it is unknown
whether these personalised measures are useful to this
population. Having this in mind, and acknowledging the
importance of this topic, in this project we will explore
to what extent a personalised outcome measurement
system, with PGOM’s, can be used in substance misuse.
To achieve this goal, we will, on the one hand, investigate
if PGOM’s are psychometrically robust to measure psycho-
logical changes in this context; and, on the other hand, to
explore the experiences of patients with those measures.
Guidelines for future use and recommendations for clinical
policies will be derived from these data in an International
Platform for Personalising Addiction Treatment.
More specifically, our aims are:
1. To study the quantitative and qualitative properties
of PGOM’s in this population
2. To investigate the experiences of patients using
personalised outcome measurement and the
feasibility of this approach, from their point of view
(e.g. easiness of understanding, comfort in use)
3. To exchange knowledge about personalised outcome
measurement towards the development of a
guidance document to use this approach in
substance misuse treatment settings (e.g. when to
use PGOM’s and under what circumstances,
recommended frequency of use)
Methods/design
To achieve the aforementioned aims, we will collect data
at four units specialising in substance misuse treatment
in Portugal, of which two target misuse of drugs (licit/
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outpatient units and one is a therapeutic community. All
these units provide assessment, treatment and advice for
addiction-related problems.
Sample and inclusion/exclusion criteria
The target sample for this project includes male and
female adult (>18 years old) patients seeking treatment
for drug and alcohol dependence at the four treatment
sites. All patients starting (first treatment episode) or be-
ing re-admitted (new treatment episode after treatment
drop-out) for treatment at these sites will be invited to
participate in the study. Re-admission for treatment oc-
curs whenever patients have dropped-out of the last
treatment episode for a period longer than 8–12 months.
Patients are excluded based on 1) lack of interest or motiv-
ation to take part and 2) being non-Portuguese speakers.
On sample size, a minimum set of 100 pairs of question-
naires (pre-post) is expected to provide tight confidence
intervals on correlations between the measures [8].
Measurements
Four outcome measures of psychological well-being will
be used, of which two are PGOM’s and the other two are
standardised. The PGOM’s are PSYCHLOPS [6], a self-
report questionnaire for patients to generate and score
two items about Problems, one about Function and one
about Well-being; and PQ [Elliott: Simplified Personal
Questionnaire Procedure, unpublished] [11], an interview-
based questionnaire for patients to generate, rank order
and score an unlimited list of personal complaints, in
whichever topic. Two PGOM’s were selected to explore
patients’ preferences about PGOM’s with different charac-
teristics (e.g. pre-set vs. non pre-set domains).
The standardised measures are CORE-OM [12,13], a
34-item self-report measure of psychological well-being.
CORE-OM was preferred over other measures used in this
population because it is mental health specific (unlike SF
Health Survey) and covers risk behaviours (unlike SF
Health Survey & BSI); and PHQ-9 [14], a self-report mood
disorders scale often included with CORE-OM in out-
come studies. A fifth outcome instrument, TOP [15], will
be included to collect data about the patient’s drug-related
situation. TOP is a brief scale to monitor and evaluate key
domains for drug-treatment, namely: Drug and alcohol
use; Injecting risk behaviours; Offending and criminal in-
volvement; and Health and Social functioning.
PQ, CORE-OM and PHQ-9 will be input in IPPS, the
software developed by our team [3,4] to facilitate data
management.
Data collection strategy
Quantitative and qualitative data will be collected for
this project in two phases. The first involves a pre-poststudy that will follow a methodology similar to previous
outcome studies in the field of substance misuse [16]. It
will comprise 2 evaluation moments:
 Pre-treatment (evaluation 1) administration of PQ,
PSYCHLOPS, CORE-OM and PHQ-9, presented in
randomised order, as well as TOP. This pre-
treatment moment will thus involve the generation
of the items in PGOM’s, followed by their scoring;
the scoring of the standardised measures; and
completion of a socio-demographic and treatment
history form.
 Three to five months after treatment entry
(evaluation 2), in which the aforementioned
outcome measures will be re-administered to the
same patients who completed evaluation 1 (paired
sample). Regarding PGOM’s, in this second
evaluation moment, patients may chose to delete
and/or add new items.
The second phase of data collection will comprise
focus groups with patients that participated in the pre-
post study. The data collected in these two phases will
be used in 3 studies, as explained in the next sections.
See Figure 1 for a diagram with the study flow.
Study 1: How reliable and sensitive to change are PGOM’s
and standardised measures in substance misuse
treatment?
In this quantitative study, the pre-post scores provided by
patients in PGOM’s (PQ and PSYCHLOPS) and standar-
dised (CORE-OM and PHQ-9) measures will be com-
pared according to several psychometric parameters of
reliability and change sensitivity, namely: Internal reliabil-
ity; Mean improvement rates; Sensitivity to change (effect
size); and Convergent validity. This analytical procedure
will replicate the methodology adopted by Ashworth et al.
in a similar study [8].
Study 2: Do PGOM’s add relevant information to
standardised measures?
In this study, we will identify the range and nature of
problems generated by PGOM’s and compare these with
domains covered by standardised measures. This study
will involve the categorization of patient-generated items
provided in PQ & PSYCHLOPS at both evaluation mo-
ments. The categorization will follow a grounded theory
approach and will be performed independently by two
judges (post-graduate students in addiction psychology).
Disagreements will be discussed until a final list of cat-
egories of problems is obtained. Then, as in Ashworth
et al. [5], we will explore the content similarity between
the categories elicited by PQ & PSYCHLOPS vs. do-
mains covered by standardised measures.
Figure 1 Study flow and research questions to be explored during the project.
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about personalised outcome assessment?
Focus groups will be implemented to study what pa-
tients think about PGOM. As in Crawford et al. [17], pa-
tients recruited for the pre-post study will be invited and
evenly distributed into four focus groups (i.e. at least
one group per research site). We expect a minimum of 5
patients per each focus group. At these groups, we will
review the 5 outcome measures used in the pre-post
study and discuss their experiences whilst answering to
them, based on questions proposed by Stone & Elliott
[18]: the helpful, hindering and difficult but OK aspects
of the assessments, including suggestions for improve-
ment. Content analysis will be conducted on the topics
elicited. Additionally, patients will be also asked to rate
each measure (in a 5-point scale) for: Relevance of cov-
ered topics; Comfort with information disclosed; Applic-
ability in this population; Ease of understanding; and
Overall satisfaction with use.
Development of guidelines
The final stage of this project involves the development
of guidelines on personalised outcome measurement, to
inform therapists on how to involve patients in sub-
stance misuse treatment, as proposed by health author-
ities [19]. These guidelines will be developed in the
context of a research network, the International Ex-
change Platform on Personalising Addiction Treatment
and will be based on the results of this project and
previous / on-going work of the research network mem-
bers. It will focus on: The patient perspective aboutpersonalised outcome measurement; Potentialities and
practical aspects of personalised outcome measurement
(e.g. which measures; when to evaluate); Best-practice
principles, challenges and barriers to its implementation;
and Future research recommendations.
Ethics and data protection
Ethical approval for this project has been obtained from
the ethics committee of the Health Region Administra-
tion of Lisbon (ARSLVT), Portugal. All patient data will
be de-identified and the patient’s identity and personal
details will be omitted whenever required (e.g. as pa-
tients are asked to generate their own contents, they
may provide, written or verbally, details that identify
others, such as names or places1).
Discussion
This project was designed using an innovative approach
to involving patients in the evaluation of (their own)
treatment, the personalised outcome measurement ap-
proach. This approach provides patients with the oppor-
tunity to put some input in which topics are used to
evaluate and monitor the progress of their treatment.
As previously explained, the personalised outcome
measurement strategy has never been implemented in
substance misuse treatment settings. For this reason, we
believe that this approach is a potential tool to help
shifting the paradigm towards a greater involvement of
patients in substance misuse treatment, potentially lead-
ing to a better adjustment of treatment to the patient’s
needs and, ultimately, avoiding early treatment drop-out.
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validity and sensitivity to change of PGOM’s in comparison
with traditional measures of psychological well-being, in
this population. In previous studies with other clinical
populations, the results showed that PGOM’s are poten-
tially powerful tools for outcome measurement purposes
in therapeutic practice, as well as group and case study
research [Elliott, Wagner, Sales, Rodgers, Alves & Café:
Psychometrics of the Personal Questionnaire: A Client-
Generated Outcome Measure, in preparation]. Our findings
will contribute to this growing body of research, comple-
menting this important work.
Besides studying the quantitative and qualitative prop-
erties of PGOM’s, this project takes a step further by
asking patients about their experience whilst responding
to different types of outcome measures. This is an im-
portant part of the project, for it will show which mea-
sures are preferred by patients and what are their
perspectives on implementing this outcome measure-
ment approach in their treatment.
By studying the psychometric properties of PGOM’s in
this population and exploring what patients think and
feel about using them, we will be able to generate, in an
international and multidisciplinary platform, a guidance
document that will help clinicians and researchers taking
this personalised strategy on board. The development of
clinical guidelines is a procedure often derived by ex-
perts (either clinicians or researchers) based on the evi-
dence available, overlooking the patient perspectives. In
our project, however, we will overcome this limitation by
combining, on the one hand, the findings of our empir-
ical studies, but also the perspectives of patients about
each measure.
Data collection for this project began in April 2013
and we anticipate it to end in mid 2014. Analyses are ex-
pected to begin in the second half of 2014. To date, ap-
proximately 40% of the target sample has already
completed the pre-treatment evaluation moment. The
re-administration of the instruments (post-treatment
evaluation) has begun as well and the first focus groups
are expected to be held between December 2013 and
January 2014.
It is also worth mentioning that, so far, only 4 out of
40 patients invited to take part in the study declined to
participate, which shows the high level of adherence and
acceptance that this project is having in this setting.
To date, our experience in this project has shown us
that both service providers and patients are motivated to
contribute to reducing the gap between science and
practice, by joining efforts to improve the treatment
which is provided in real clinical settings. Ultimately,
we believe that treatment provision, and the evaluation
of its outcomes, should take on board the perspectives
of all parties involved in the process, from servicemanagers, therapists and, most importantly, patients, so
that healthcare may be designed to meet the real needs
of its target population.
Endnote
1Examples: “I think that my neighbor John Stuart hates
me”, “I don’t trust in Dr. Bolton anymore”.
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